Like fingolimod, which is already approved for the treatment of MS,<unk>  blocks the sphingosine-1-phosphate receptor. This mechanism prevents lymphocytes (a type of white blood cells) from leaving lymph nodes.<unk>  is selective for subtype 1 of this receptor, S1P1.
Ponesimod
Ozanimod
Siponimod
Fingolimod
Caplacizumab
Sarilumab
Benralizumab
Atezolizumab